Estados financieros detallados de Calidi Biotherapeutics, Inc. (CLDI): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.17, CLDI presenta beneficios negativos (P/E no significativo) y un ROE del -372.86%. La capitalización bursátil es de $1M.
Cuenta de Resultados (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | $449000 | $45000 | 0 | 0 | 0 |
| Coste de Ventas | 0 | $94000 | $274000 | $1.3M | 0 | $1.7M |
| Beneficio Bruto | 0 | $355000 | -$229000 | -$1.3M | 0 | -$1.7M |
| I+D | $3.2M | $4.7M | $7.3M | $13.0M | $8.9M | $9.7M |
| Generales y Administrativos | $3.6M | $6.2M | $15.6M | $16.0M | $12.9M | $10.5M |
| Gastos Operativos | $6.8M | $10.8M | $22.9M | $27.7M | $21.8M | $18.6M |
| Beneficio Operativo | -$6.8M | -$10.5M | -$23.1M | -$29.0M | -$21.8M | -$20.2M |
| EBITDA | -$6.7M | -$9.4M | -$25.0M | -$24.2M | -$19.7M | -$18.2M |
| Gastos por Intereses | $163000 | $614000 | $158000 | $3.7M | $933000 | $207000 |
| Beneficio Antes de Impuestos | -$7.9M | $3.4M | -$25.4M | -$29.2M | -$22.2M | -$20.0M |
| Impuestos | $4000 | $11000 | $11000 | $16000 | $14000 | $15000 |
| Beneficio Neto | -$7.9M | -$10.9M | -$25.4M | -$29.2M | -$22.1M | -$19.9M |
| BPA | $-42.24 | $226.56 | $-5740.80 | $-3321.76 | $-571.20 | $-95.20 |
| BPA Diluido | $-42.24 | $226.56 | $-5740.80 | $-3321.76 | $-571.20 | $-95.20 |
| Acciones en Circulación (Diluidas) | $186265 | $14914 | $4412 | $8760 | $41526 | $268875 |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | -$426000 | 0 |
| Beneficio Operativo | -$5.0M | -$4.5M | -$4.2M | -$4.2M |
| EBITDA | -$4.7M | -$3.6M | -$3.6M | -$4.1M |
| Beneficio Neto | -$5.1M | -$4.1M | -$4.1M | -$4.2M |
| BPA | $-35.36 | $-8.96 | $-6.88 | $-2.94 |
| BPA Diluido | $-35.36 | $-8.96 | $-6.88 | $-2.94 |
Balance (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $420000 | $2.1M | $372000 | $2.0M | $9.6M | $5.6M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | $1.4M | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $513000 | $2.7M | $786000 | $4.3M | $10.2M | $6.3M |
| Inmovilizado Material | $723000 | $585000 | $1.1M | $5.3M | $2.9M | $1.7M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $1.9M | $3.4M | $2.6M | $10.0M | $14.2M | $8.9M |
| Cuentas por Pagar | $822000 | $624000 | $2.1M | $2.9M | $2.1M | $595000 |
| Deuda a Corto | $4.9M | $5.0M | $5.4M | $807000 | $3.2M | 0 |
| Pasivos Corrientes | $8.9M | $26.0M | $43.0M | $10.2M | $9.5M | $3.9M |
| Deuda a Largo | $6.4M | 0 | 0 | $2.1M | $600000 | $600000 |
| Pasivos Totales | $24.3M | $26.0M | $53.0M | $18.3M | $12.2M | $5.1M |
| Reservas | -$34.4M | -$44.9M | -$70.4M | -$99.6M | -$121.7M | -$141.6M |
| Patrimonio Neto | -$22.5M | -$22.6M | -$50.4M | -$8.2M | $1.5M | $3.8M |
| Deuda Total | $11.7M | $5.2M | $6.0M | $7.2M | $7.0M | $2.6M |
| Deuda Neta | $11.3M | $3.0M | $5.6M | $5.2M | -$2.6M | -$3.0M |
| Capital Circulante | -$8.4M | -$23.2M | -$42.2M | -$5.9M | $731000 | $2.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $10.4M | $5.6M | $6.6M | $4.1M |
| Activos Totales | $14.0M | $8.9M | $9.6M | $7.2M |
| Pasivos Totales | $6.8M | $5.1M | $4.7M | $4.1M |
| Patrimonio Neto | $6.9M | $3.8M | $4.9M | $3.1M |
| Deuda Total | $3.1M | $2.6M | $2.3M | $1.9M |
Flujo de Caja (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$7.9M | -$10.9M | -$25.4M | -$29.2M | -$22.2M | -$20.1M |
| Amortizaciones | $184000 | $153000 | $253000 | $1.3M | $1.5M | $1.7M |
| Compensación en Acciones | $968000 | $1.3M | $6.1M | $4.8M | $3.0M | $2.1M |
| Cambio en Capital Circulante | $945000 | $1.1M | $3.6M | -$6.2M | -$1.7M | -$4.7M |
| Flujo de Caja Operativo | -$4.8M | -$7.8M | -$13.2M | -$27.0M | -$19.7M | -$21.3M |
| Inversiones (CapEx) | -$351000 | -$206000 | -$428000 | -$585000 | -$16000 | -$120000 |
| Adquisiciones | 0 | 0 | 0 | $9000 | 0 | -$50000 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$5.2M | -$8.0M | -$13.6M | -$27.6M | -$19.7M | -$21.4M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$4.2M | -$5.0M | -$4.1M | -$4.4M |
| Inversiones (CapEx) | -$27000 | -$29000 | -$5000 | $5000 |
| Flujo de Caja Libre | -$4.3M | -$5.1M | -$4.1M | -$4.3M |
| Dividendos Pagados | 0 | 0 | 0 | -$309000 |
| Compensación en Acciones | $529000 | $450000 | $231000 | $157000 |
Crecimiento y Márgenes (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | -90.0% | -100.0% | | |
| Crecimiento Beneficio Neto (anual) | | -37.7% | -132.6% | -14.9% | +24.2% | +10.1% |
| Crecimiento BPA (anual) | | +636.4% | -2633.9% | +42.1% | +82.8% | +83.3% |
| Cambio en Acciones (anual) | | -92.0% | -70.4% | +98.5% | +374.0% | +547.5% |
| Crecimiento FCF (anual) | | -54.1% | -71.0% | -102.1% | +28.5% | -8.6% |
| Margen Bruto | | 79.1% | -508.9% | | | |
| Margen Operativo | | -2334.5% | -51395.6% | | | |
| Margen EBITDA | | -2104.7% | -55551.1% | | | |
| Margen Neto | | -2435.0% | -56504.4% | | | |
| Margen FCF | | -1777.3% | -30315.6% | | | |
| Tasa Impositiva Efectiva | -0.1% | 0.3% | -0.0% | -0.1% | -0.1% | -0.1% |
Datos por Acción (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-27.79 | $-535.07 | $-3092.02 | $-3147.03 | $-474.64 | $-79.64 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $186265 | $14914 | $4412 | $8760 | $41526 | $268875 |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -372.86% |
| Rentabilidad sobre capital invertido | -347.09% |
| Rentabilidad sobre activos | -242.55% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.62 |
| Ratio corriente | 1.68 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -29.02 |
Ratios Clave (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -444.55 | 83.14 | -3.40 | -0.87 | -0.39 | -0.20 |
| P/VC | -155.59 | -12.42 | -1.71 | -3.08 | 5.98 | 1.34 |
| P/V | 0.00 | 625.63 | 1914.46 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 79.1% | -508.9% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | -2334.5% | -51395.6% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | -2435.0% | -56504.4% | 0.0% | 0.0% | 0.0% |